Psoriasis
Therapeutic area
Immunology
Rare disease
No
- Definition
- An autoimmune condition characterized by red, well-delineated plaques with silvery scales that are usually on the extensor surfaces and scalp. They can occasionally present with these manifestations: pustules; erythema and scaling in intertriginous areas, and erythroderma, that are often distributed on extensor surfaces and scalp.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Psoriasis
- Alternative names
- psoriasis
- Therapeutic area
- Immunology
- Severity
- Mild
- Genetic
- Hereditary
- Inflammatory
- Dermatology
- Immunology
- MONDO ID
- MONDO:0005083
- Parent condition
- MONDO:0002406
Related records
Broader conditions (13)
- Dermatitis
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Hereditary disease
- Hereditary skin disorder
- Human disease
- Immune system disorder
- Inflammatory disease
- Integumentary system disorder
- Skin disorder
Narrower conditions (6)
- Generalized pustular psoriasis
- Guttate psoriasis
- Palmoplantar pustulosis
- Psoriasis 14, pustular
- Psoriasis 2
- Pustular psoriasis
Trials (1,456)
- 12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN
- 1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat
- 308nm Excimer Laser for Treatment of Fingernail Psoriasis
- 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
- A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
- A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
- A 36-Week Extension to Protocol ISA04-03
- A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis
- A Basket Trial of Vunakizumab in Inflammatory Skin Diseases
- A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab
- A Canadian Open-Label Access Program to Evaluate Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriasis
- A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
- A Clinical Evaluation of Marula-Derived Ceramide Cream on Skin Barrier Function Enhancement
- A Clinical Investigation With Epaderm® Cream
- A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis
- A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis
- A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
- A Clinical Study of TQH2929 in Healthy Adult Subjects
- A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
- A Clinical Trial of Antiplatelets in Psoriasis
Approved drugs (46)
- Acitretin
- Adalimumab
- Anthralin
- Apremilast
- Bergapten
- Betamethasone dipropionate
- Bimekizumab
- Brodalumab
- Calcipotriene
- Calcitriol
- Clobetasol propionate
- COAL TAR
- Cyclosporine
- Desoximetasone
- Deucravacitinib
- Dexamethasone
- Dexamethasone sodium phosphate
- Dimethyl fumarate
- Efalizumab
- Etanercept
Drugs in development (158)
- Abacavir hydroxyacetate Phase 2
- Abacavir sulfate Phase 1
- Abatacept Phase 2
- Abrocitinib Phase 2
- Adriforant Phase 2
- Alefacept Phase 3
- Alitretinoin Phase 2
- AMG-557 Phase 1
- AMG-811 Phase 1
- Aminopterin Phase 2
- Amiselimod hydrochloride Phase 2
- Ammonium trichlorotellurate Phase 2
- Atorvastatin Phase 3
- Baricitinib Phase 2
- Bazlitoran Phase 2
- Becocalcidiol Phase 2
- Belapectin Phase 2
- Belnacasan Phase 2
- Belumosudil Phase 2
- Bermekimab Phase 2
Other linked drugs (3)
- Ammonia N 13
- Liraglutide
- Menthol